thyrotropin-releasing hormone receptor

thyrotropin-releasing hormone receptor
Name	Thyrotropin-releasing hormone receptor

Contents

thyrotropin-releasing hormone receptor

The thyrotropin-releasing hormone receptor is a G protein–coupled receptor discovered through molecular cloning efforts tied to studies at institutions like Harvard University, National Institutes of Health, and University of Cambridge; it mediates responses to the neuropeptide thyrotropin-releasing hormone and links neuroendocrine circuits studied by researchers at Max Planck Society, King's College London, and Columbia University. Early characterization involved collaborations between laboratories associated with Nobel Prize–winning work on signal transduction, techniques developed at Cold Spring Harbor Laboratory, and structural methods advanced at Stanford University. The receptor has been a focus of translational programs at pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Roche.

Structure and molecular properties

The receptor is a seven-transmembrane domain protein characterized using crystallography and cryo-electron microscopy strategies pioneered at European Molecular Biology Laboratory, The Scripps Research Institute, and Riken; structural models reference fold motifs described in work from University of Oxford, Massachusetts Institute of Technology, and California Institute of Technology. Biochemical analysis used affinity purification approaches from teams at Johns Hopkins University, University of Pennsylvania, and Yale University, and revealed conserved residues analogous to sites studied in other Class A GPCRs by groups at University College London, ETH Zurich, and University of Tokyo. Post-translational modifications including N-linked glycosylation and phosphorylation were mapped using mass spectrometry pipelines developed at European Bioinformatics Institute, Broad Institute, and National Center for Biotechnology Information.

The gene encoding the receptor was cloned in parallel by laboratories at Howard Hughes Medical Institute, University of California, San Diego, and University of Chicago, and mapped to a chromosomal locus defined using cytogenetic approaches refined at Wellcome Trust Sanger Institute, European Cytogeneticists Association, and Cold Spring Harbor Laboratory. Expression profiling employed in situ hybridization and RNA sequencing technologies from groups at Roche Sequencing Solutions, Illumina, and Genentech, revealing enriched expression in hypothalamic nuclei identified in atlases from Allen Institute for Brain Science, National Institute of Mental Health, and University of California, Los Angeles. Developmental and tissue-specific regulation was compared with gene networks studied by consortia including ENCODE, GTEx Consortium, and Human Cell Atlas.

The receptor couples primarily to Gq/11 heterotrimeric G proteins, a signaling paradigm elaborated by researchers at University of California, Berkeley, Laboratory of Molecular Biology, and Yale School of Medicine; activation triggers phospholipase C pathways first described in experiments from The Rockefeller University, University of Michigan, and University of Toronto. Ligand binding kinetics and pharmacological agonists and antagonists were characterized by medicinal chemists from Merck, AstraZeneca, and Bristol-Myers Squibb using assays standardized by International Union of Pharmacology, American Society for Pharmacology and Experimental Therapeutics, and European Pharmacopoeia. Allosteric modulators, biased agonism, and inverse agonists were explored with techniques from Salk Institute, Novartis Institutes for BioMedical Research, and Duke University, integrating high-throughput screening methods pioneered at Broad Institute, Harvard Medical School, and Cold Spring Harbor Laboratory.

Physiologically, the receptor regulates hypothalamic–pituitary–thyroid axis activity, a neuroendocrine circuit elucidated in classic studies at University of Cambridge, University of Edinburgh, and Karolinska Institutet; this function intersects regulatory pathways investigated by teams at Max Planck Institute for Psychiatry, Institut Pasteur, and National Institute of Neurological Disorders and Stroke. Beyond thyroid regulation, receptors modulate autonomic, metabolic, and behavioral responses characterized in research at Columbia University Medical Center, University of California, San Francisco, and McGill University; interactions with neurotransmitter systems were mapped using connectomics resources from Allen Institute for Brain Science, Human Connectome Project, and Donders Institute. Regulatory controls include receptor desensitization and internalization mechanisms studied by groups at University of Washington, Yale School of Medicine, and Karolinska Institutet.

Alterations in receptor function have been implicated in clinical phenotypes evaluated in cohorts from National Institutes of Health, Mayo Clinic, and Cleveland Clinic, including congenital hypothyroidism and neuropsychiatric conditions examined by consortia such as Psychiatric Genomics Consortium, European Thyroid Association, and American Thyroid Association. Pharmacogenomic variability and rare mutations were reported in population studies coordinated through UK Biobank, 1000 Genomes Project, and Exome Aggregation Consortium, and have informed diagnostic frameworks used at Children's Hospital of Philadelphia, Great Ormond Street Hospital, and Mount Sinai Health System. Therapeutic modulation has been assessed in clinical trials registered by networks including ClinicalTrials.gov, European Medicines Agency, and National Cancer Institute.

Tools to study the receptor include knockout and transgenic models developed at Jackson Laboratory, European Mouse Mutant Archive, and Mutant Mouse Resource Center; pharmacological tool compounds and radioligands were synthesized in chemistry programs at AstraZeneca, GlaxoSmithKline, and academic laboratories at University of Illinois Urbana-Champaign, Indiana University Bloomington, and University of Groningen. Structural biology platforms from Max Planck Institute for Biophysical Chemistry, European Synchrotron Radiation Facility, and National Center for Electron Microscopy support rational drug design efforts pursued by collaborations between Novartis, Merck, and academic centers including Massachusetts General Hospital, Mount Sinai School of Medicine, and Vanderbilt University Medical Center. Emerging modalities such as biased ligands, peptide mimetics, and gene therapy approaches are being explored through partnerships involving Bill & Melinda Gates Foundation, Wellcome Trust, and translational programs at Imperial College London.